Mardin Fallah
Chief Executive Officer & Founder RNARevive
Seminars
Thursday 28th May 2026
Redesigning Self-Amplifying RNA to Enable Durable, Low-Dose In Vivo Therapeutic Reprogramming
3:30 pm
- Extend therapeutic expression from days to months by redesigning intracellular control of self-amplifying RNA to support sustained, low-frequency dosing beyond vaccine-optimized kinetics
- Expand saRNA applicability into chronic and tissue-specific indications by overcoming rapid clearance and homogeneous expression through synthetic biology modification of UTRs and replicase machinery
- Enable scalable, cost-effective alternatives to ex vivo cell therapies and complex biologics by positioning in vivo saRNA-driven reprogramming as a practical therapeutic platform for osteoporosis, ophthalmology, and rare diseases
